Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06517199
PHASE3

Olanzapine for Cancer Related Anorexia-cachexia Syndrome

Sponsor: Mahidol University

View on ClinicalTrials.gov

Summary

Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.

Official title: Randomized Placebo-controlled Study of Olanzapine for Cancer Related Anorexia-cachexia Syndrome

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

138

Start Date

2024-01-22

Completion Date

2026-01-21

Last Updated

2024-07-24

Healthy Volunteers

No

Interventions

DRUG

Olanzapine 2.5 MG

olanzapine 2.5 mg/day for 28 days

DRUG

Olanzapine 5 MG

olanzapine 5 mg/day for 28 days

DRUG

Placebo

placebo 1 tab/day for 28 days

Locations (2)

Faculty of Medicine Siriraj Hospital

Bangkok, Thailand

Division of medical oncology, department of medicine Siriraj Hospital

Bangkok, Thailand